ANAMU, MORINGA, SPIRULINA, AND CHLORELLA: CONTRIBUTION TO THE QUALITY OF LIFE OF ONCOLOGY PATIENTS – RESULTS OF THE POST-MARKETING PROSPECTIVE STUDY PERFORMED IN SERBIA IN 2021 – 2022

  • Anabely Estevez Garcia International Health Center, La Pradera, Cuba
  • Vladimir Kovčin Oncomed-System
  • Aliuska Venegas Godinez International Health Center, La Pradera, Cuba
Keywords: malignant tumors, quality of life, anamu, chlorella, moringa, spirulina

Abstract


Introduction: The quality of life is one of the priority goals in the treatment of oncology patients. In addition to conventional therapies, symptomatic and supportive treatments are valuable for the final treatment outcome. Many such patients resort to alternative methods, such as herbal therapy.

Study aim: This prospective study aimed to assess the effect of the plants: anamu, moringa, spirulina, and chlorella, which are routinely used in Cuba, on the quality of life of oncology patients.

Materials and methods: Forty-six patients with various stage four malignant tumors were examined. Of the 46 patients, 26 were on chemotherapy, while 18 were on symptomatic and supportive therapy. The patients used extracts of the afore-mentioned plants orally, for three months. With prior consent and authorization, the standard EORTC QLQ-C30 questionnaire, written in the patients' native language, was used to assess quality of life, before and after three months of use.

Results: According to patient ratings, overall assessment of patient general health status and quality of life showed significant improvement after three months of use of the extracts, as compared to the beginning of application. According to the questionnaire, all five parameters improved on the functional scale (Table 2, Graph 2), (p = 0.0002338), and the scores on the symptoms scale also improved (fatigue, p = 0.01501; pain, p = 0 ,0436). Women achieved better physical functionality and significant loss of fatigue and pain, while cognitive functionality improved in men. Emotional functionality improved in the subgroup of patients who were receiving chemotherapy, while in those who had previously received chemotherapy, there were significant differences in the symptoms scale score regarding loss of appetite and constipation – symptoms that resolved after three months of product use, thus equating the subgroups in terms of the reduction of these symptoms. In other functional parameters, statistically significant differences were also obtained for all patients.

Conclusion: The improvement in the quality of life and functionality of patients, as well as the reduction in symptoms, whether the patients received chemotherapy or not, was statistically significant.

References

1. De la Cruz M, Bandiano J. Libellus de medicinalibus Indorum herbis: manuscrito azteca de 1552. 2. ed. México, D.F: Fondo de Cultura Económica: Instituto Mexicano del Seguro Social; 1991. 2 p.

2. Figueroa-Hernández JL, Céspedes-Cortés, Figueroa-Espitia JL. Flora Silvestre presente en un nuevo asentamiento urbano en la Delegación de Xochimilco en México, D.F. In: XXVI Congreso Nacional de Farmacología; 2004 Мay 25-28; Morelia, Michoacán, Mexico.

3. Greenlee H, Balneaves LG, Carlson LE, Cohen M, Deng G, Hershman D, et al. Society for Integrative Oncology. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr. 2014 Nov;2014(50):346-58. doi: 10.1093/jncimonographs/lgu041. 

4. Lianes Barragan P, Fernández Bruno M, Martínez Peralta S. Medicina Integrativa en el paciente oncológico. In: Escobar Álvarez Y, Blasco Cordellat A, Espinosa Arranz J, De las Peñas Bataller R, Del Mar Muñoz Sánchez M, Virizuela Echaburu JA, et al., editors. Manual de Cuidados Continuos de SEOM, 2A Edición. Madrid: Sociedad Española de Oncología Médica (SEOM); 2014. p. 489-97.

5. Bañuelos MR. Medicina integrativa en el paciente oncológico: Estrategia de la Organización Mundial de la Salud y estado actual. Revista Medica de Homeopatia. 2013;6(3):136-40. doi: 10.1016/j.homeo.2013.10.001.

6. Shike M, Brennan MF. Supportive care of the cancer patient. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice in Oncology. Philadelphia, PA: J.B. Lippincott; 1989. P. 2029-44.

7. Deng GE, Frenkel M, Cohen L, Cassileth BR, Abrams DI, Capodice JL, et al. Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol. 2009;7(3):85-120.

8. Thinking About Complementary and Alternative Medicine: A Guide for People with Cancer. National Institutes of Health.

9. Heber D, Blackburn GL, Go VLW. Introduction: The principles of nutrition oncology. In: Heber D, Blackburn GL, Go VLW. Nutritional Oncology. San Diego, CA: Academic Press; 1999. p. 1-10.

10. Lemus Rodríguez Z, García Pérez ME, Batista Duharte A, De la Guardia Peña O, Alfonso Castillo A. La tableta de anamú: un medicamento herbario inmunoestimulante. MEDISAN. 2004;8(3).

11. García Pérez ME, Lemus Rodríguez Z, Hung Arbelo M., Vistel Vigo M. Influence of polyvinylpyrrolidone, microcrystalline cellulose and colloidal silicon dioxide on technological characteristics of a high-dose Petiveria alliacea tablet. Drug Dev. Ind. Pharm. 2017 Dec; 43(12):2011-5. doi: 10.1080/03639045.2017.1359621.

12. Jovicevic L, Troiani MP, Capezzone de Joannon A, Saso L, Mazzanti G, Rossi V. In vitro antiproliferative activity of Petiveria alliacea L. on several t tumor cell lines. Pharmacol Res. 1993;27(S1):105-6. doi: https://doi.org/10.1006/phrs.1993.1087.

13. Marini S, Jovicevic L, Milanese C, Giardina B, Leone MG. Effects of Petiveria alliacea L. on cytokine production and natural killer cell activity. Pharmacol Res. 1993;27(S1):107-8. doi: https://doi.org/10.1006/phrs.1993.1088.

14. Williams LAD, The TL, Gardner MT, Fletcher CK, Naravane A, Gibbs N, et al. Immunomodulatory activities of Petiveria alliacea L. Phytother Res. 1997;11(3):251-3. doi: 10.1002/(sici)1099-1573(199705)11:3<251::aid-ptr75>3.0.co;2-b.

15. Kubec R, Musah R. Cysteine sulfoxide derivatives in Petiveria alliacea. Phytochemistry. 2001 Nov;58(6):981-5. doi: 10.1016/s0031-9422(01)00304-1.

16. Queiroz ML. Cytokine profile and natural killer cell activity in Listeria monocytogenes infected mice treated orally with Petiveria alliacea extract. Immunopharmacol Immunotoxicol. 2000 Aug;22(3):501-18. doi: 10.3109/08923970009026008.

17. Urueña C, Cifuentes C, Castañeda D, Arango A, Kaur P, Asea A, et al. Petiveria alliacea extracts multiple mechanisms to inhibit growth of human and mouse ttumoral cells. BMC Complement Altern Med. 2008;8(60). doi: 10.1186/1472-6882-8-60.

18. Anwar F, Latif S, Ashraf M, Gilani AH. Moringa Oleifera: a food plant with multiple medicinal uses. Phytother Res. 2007 Jan;21(1):17-25. doi: 10.1002/ptr.2023. 

19. Kasolo JN, Bimenya GS, Ojok L, Ochieng J, Ogwal-Okeng JW. Phytochemicals and uses of Moringa Oleifera leaves in Ugandan rural communities. J Med Plants Res. 2010;4(9):753-7.

20. Vats S, Grupta T. Evaluation of bioactive compounds and antioxidant potential of hydroethanolic extract of Moringa Oleifera Lam from Rajasthan, India. Physiol Mol Biol Plants. 2017 Jan;23(1):239-48. doi: 10.1007/s12298-016-0407-6.

21. Mehta S, Rai PK, Rai NK, Rai AK, Bicanic D, Watal G. Role of spectral studies in detection of antibacterial phytoelements and phytochemicals of Moringa Oleifera. Food Biophys. 2011 Jun;6(4):497-502. doi: 10.1007/s11483-011-9231-2.

22. Jung IL. Soluble extract from Moringa Oleifera leaves with a new anticancer activity. PLoS One. 2014 Apr;9(4):e95492. doi:10.1371/journal.pone.0095492.

23. Kitts DD, Weiler K. Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery. Curr Pharm Des. 2003;9(16):1309-23. doi: 10.2174/1381612033454883.

24. Lopez-Sanchez J, Ponce-Alquicira E, Pedroza-Islas R, de la Peña Diaz A, Soriano-Santos J. Effects of heat and pH treatments and in vitro digestion on the biological activity of protein hydrolysates of Amaranthus hypochondriacus L. grain. J Food Sci Technol. 2016 Dec;53(12):4298-307. doi: 10.1007/s13197-016-2428-0.

25. Singh BP, Vij S, Hati S. Functional significance of bioactive peptides derived from soybean. Peptides. 2014 Apr;54:171-9. doi: 10.1016/j.peptides.2014.01.022.

26. Nair SS, Kavrekar V, Mishra A. In vitro studies on alpha amylase and alpha glucosidase inhibitory activities of selected plant extracts. Eur J Exp Biol. 2013;3(1):128-32.

27. Rebello CJ, Greenway FL, Finley JV. A review of the nutritional value of legumes and their effects on obesity and its related co-morbidities. Obes Rev. 2014 May;15(5):392-407. doi: 10.1111/obr.12144.

28. Sreelatha S, Jeyachitra A, Padma PR. Antiproliferation and induction of apoptosis by Moringa Oleifera leaf extract on human cancer cells. Food Chem Toxicol. 2011 Jun;49(6):1270-5. doi: 10.1016/j.fct.2011.03.006.

29. Cáceres A, Girón LM, Alvarado SR, Torres MF. Screening of antimicrobial activity of plants popularly used in Guatemala for the treatment dermatomucosal diseases. J Ethnopharmacol. 1987 Aug;20(3):223-37. doi: 10.1016/0378-8741(87)90050-x.

30. Guevara AP, Vargas C, Sakurai H, Fujiwara Y, Hashimoto K, Maoka T, et al. An antittumor promoter from Moringa Oleifera Lam. Mutat Res. 1999 Apr;440(2):181-8. doi: 10.1016/s1383-5718[99]00025-X.

31. Costa-Lotufo LV, Khan MT, Ather A, Wilke DV, Jimenez PC, Pessoa C, et al. Studies of the anticancer potential of plants used in Bangladeshi folk medicine. J Ethnopharmacol. 2005 May 13;99(1):21-30. doi: 10.1016/j.jep.2005.01.041.

32. Lee L, Rodriguez J, Tsukiyama T. Chromatin remodeling factors Isw2 and Ino80 regulate checkpoint activity and chromatin structure in S phase. Genetics. 2015 Apr;199(4):1077-91. doi: 10.1534/genetics.115.174730.

33. Sanchez-Machado DI, Nuñez-Gastelum JA, Reyes-Moreno C, Ramírez-Wong B, López-Cervantes J. Nutritional quality of edible parts of Moringa oleifera. Food Anal Method. 2010;3:175-80. doi: 10.1007/s12161-009-9106z.

34. Mirzaie S, Zirak-Khattab F, Hosseini SA, Donyaei-Darian H. Effects of dietary Spirulina on antioxidant status, lipid profile, immune response and performance characteristics of broiler chickens reared under high ambient temperature. Asian-Australas J Anim Sci. 2018 Apr;31(4):556-63. doi: 10.5713/ajas.17.0483.

35. Hidalgo-Lucas S, Rozan P, Guérin-Deremaux L, Baert B, Violle N, Saniez-Degrave MH, et al. Benefits of Preventive Administration of Chlorella sp. on Visceral Pain and Cystitis Induced by a Single Administration of Cyclophosphamide in Female Wistar Rat. J Med Food. 2016 May;19(5):450-6. doi: 10.1089/jmf.2015.0077.

36. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.39. 

37. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A; On behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual [3rd Edition]. Published by: European Organisation for Research and Treatment of Cancer, Brussels; 2001.

38. Berat S, Radulovic S. Trends in use of and attitudes held towards alternative and complementary medicine among patients treated in a Department of Medical Oncology in Serbia. A several-years apart time survey study. J BUON. 2014 Apr-Jun;19(2):535-9.

39. Gnanaselvan S, Yadav SA, Manoharan SP, Pandiyan B. Uncovering the anticancer potential of phytomedicine and polyherbal's synergism against cancer – A review. Biointerface Research. 2023;13(4):356. doi: 10.33263/BRIAC134.356.

40. Nikolic I, Smiljenic D, Kukic B, Bogdanovic B, Petrovic T, Ivkovic-Kapicl T, et al. Application of alternative medicine in gastrointestinal cancer patients. Vojnosanit Pregl. 2012;69(11):947-50.

41. Luketina-Šunjka M, Rančić N, Subotić S, Jakovljević M. Complementary and alternative medicine in Serbia: A literature review. Acta Medica Medianae. 2020;59(3):98-104. doi:10.5633/amm.2020.0313.

42. Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in cancer treatment: From preclinical studies to clinical practice. Front Pharmacol. 2020 Jan;10:1614. doi: 10.3389/fphar.2019.01614. 

43. Battisti NML, Reed MWR, Herbert E, Morgan JL, Collins KA, Ward SE, et al. Bridging the age gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer. Eur J Cancer. 2021 Feb;144:269-80. doi: 10.1016/j.ejca.2020.11.022.

44. Laskar YB, Lourembam RM, Mazumder PB. Herbal remedies for breast cancer prevention and treatment. In: Hassan BAR, editor. Medicinal Plants - Use in Prevention and Treatment of Diseases. IntechOpen; 2020. doi: 10.5772/intechopen.89669.

45. Caesar LK, Cech NB. Synergy and antagonism in natural product extracts: when 1+1 does not equal 2. Nat Prod Rep. 2019 Jun;36(6):869-88. doi: 10.1039/c9np00011a.

46. Abbas Z, Manoharan AL, Jagadeesan G, Nataraj G, Muniyandi K, Sathyanarayanan S, et al. Evaluation of an edible polyherbal formulation against urinary tract infection pathogens, its antioxidant and anti-inflammatory potential. Biocatal Agric Biotechnol. 2021;35. doi: 10.1016/j.bcab.2021.102104.

47. Roy A. Plumbagin: A potential anti-cancer compound. Mini Rev Med Chem. 2021;21(6):731-7. doi: 10.2174/1389557520666201116144421.

Published
2023/09/27
Section
Original articles